Enzo Biochem, Inc. (ENZ)
Stock Price Chart
Key Info
| Market Cap | 117.81M |
| Revenue (ttm) | 77.42M |
| Net Income (ttm) | -30.58M |
| Shares Out | 47.89M |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 12, 2020 |
| Last Price | $2.46 |
| Previous Close | $2.50 |
| Change ($) | -0.04 |
| Change (%) | -1.60% |
| Day's Open | 2.50 |
| Day's Range | 2.44 - 2.52 |
| Day's Volume | 249,888 |
| 52-Week Range | 1.56 - 4.85 |
More Stats
| Market Cap | 117.81M |
| Enterprise Value | 90.03M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 47.89M |
| Float | 35.44M |
| EPS (basic) | -0.65 |
| EPS (diluted) | -0.65 |
| FCF / Share | -0.35 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 2.29M |
| Short Ratio | 1.22 |
| Short % of Float | 5.92% |
| Beta | 0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 1.52 |
| PB Ratio | 1.92 |
| Revenue | 77.42M |
| Operating Income | -31.60M |
| Net Income | -30.58M |
| Free Cash Flow | -16.58M |
| Net Cash | 27.78M |
| Net Cash / Share | 0.58 |
| Gross Margin | 30.03% |
| Operating Margin | -40.82% |
| Profit Margin | -39.50% |
| FCF Margin | -21.42% |
| ROA | -17.38% |
| ROE | -39.89% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.17 | 101 | 105 | 103 | 97.60 | 95.95 | 93.71 | 103 | 102 | 97.08 |
| Revenue Growth | -19.64% | -3.88% | 2.25% | 5.3% | 1.72% | 2.39% | -9.1% | 1.03% | 5.1% | - |
| Gross Profit | 23.25 | 40.63 | 45.61 | 45.58 | 42.83 | 41.68 | 38.87 | 47.11 | 48.21 | 44.97 |
| Operating Income | 1.73 | -12.16 | -3.15 | 46.85 | -1.21 | -10.18 | -18.98 | -40.48 | -12.93 | -22.06 |
| Net Income | 2.49 | -10.32 | -2.50 | 45.29 | -2.29 | -9.98 | -18.24 | -39.27 | -12.96 | -22.23 |
| Shares Outstanding | 47.35 | 46.97 | 46.35 | 46.15 | 45.36 | 42.56 | 39.61 | 38.80 | 38.36 | 38.00 |
| Earnings Per Share | 0.05 | -0.22 | -0.05 | 0.97 | -0.05 | -0.23 | -0.46 | -1.01 | -0.34 | -0.59 |
| Operating Cash Flow | 4.81 | -2.74 | -0.21 | 53.13 | -3.70 | -1.70 | -10.02 | -5.97 | -8.33 | -13.46 |
| Capital Expenditures | -8.13 | -1.89 | -1.75 | -1.53 | -1.78 | -0.84 | -0.99 | -1.36 | -1.22 | -3.25 |
| Free Cash Flow | -3.32 | -4.62 | -1.96 | 51.60 | -5.48 | -2.54 | -11.00 | -7.34 | -9.55 | -16.72 |
| Cash & Equivalents | 60.15 | 60.04 | 64.17 | 67.78 | 18.11 | 17.46 | 9.01 | 15.08 | 24.16 | 33.57 |
| Total Debt | 4.60 | - | - | 1.56 | 3.01 | 3.01 | 3.26 | - | - | - |
| Net Cash / Debt | 55.54 | 60.04 | 64.17 | 66.22 | 15.10 | 14.44 | 5.74 | 15.08 | 24.16 | 33.57 |
| Assets | 107 | 102 | 108 | 112 | 68.39 | 64.41 | 58.96 | 69.12 | 109 | 115 |
| Liabilities | 20.61 | 20.54 | 18.79 | 22.27 | 25.79 | 27.46 | 24.83 | 20.02 | 20.76 | 18.23 |
| Book Value | 86.03 | 81.12 | 88.87 | 89.55 | 42.61 | 36.95 | 34.13 | 49.10 | 88.72 | 97.02 |
Company Profile
Company Details
| Full Name | Enzo Biochem, Inc. |
| Country | United States |
| Employees | 460 |
| CEO | Elazar Rabbani |
Stock Information
| Ticker Symbol | ENZ |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NYSE: ENZ |
Description
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in Life Sciences Products, Clinical Laboratory Services, and Therapeutics segments. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 34 patient service centers in New York and New Jersey; and a free standing ?STAT' or rapid response laboratory in New York City and Connecticut, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.